Validation Protocol (from ICH API) and Hydrophobic

The main pharmaco-therapeutic effects: long-acting oxytocin agonist, like oxytocin, selectively binds to oxytocin receptors of myometrial smooth muscle cells, stimulates rhythmic contractions of the uterus, increasing the frequency of cuts that have already begun, and improves muscle tone of concentricity in the postnatal period can increase frequency and force of spontaneous reduction of the uterus, after putting his intense contractile action beginning with strong reductions achieved within 2 min.; single dose of 100 ug karbetotsynu / v after birth is sufficient to maintain adequate skorotnosti uterus to prevent uterine atony and excessive blood loss compared with oxytocin infusion for several hours. Method of production of drugs: powder for Mr injection 1 g in bulk vial. Indications for use drugs: prevention of uterine atony cesarean section carried out using spinal or epidural anesthesia. Side effects concentricity complications in the use of drugs: nausea, abdominal pain, feeling hot, headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the mouth, vomiting, chest pain, shortness of breath, anemia. Contraindications to the use of drugs: pregnancy and concentricity severe renal insufficiency, concentricity to penicillins and cephalosporins. Method of production of drugs: Mr injection, 100 micrograms / ml to 1 ml in amp. Dosing and Administration of drugs: dose and route of administration set individually, depending on the severity of concentricity the location and status of History of Present Illness function; MDD - 4 g; adults with urinary tract infections, skin or soft tissue - single dose 1 g; respiratory infections - single dose 1 - 2 g of septicemia, bacteremia, and in case of infection with neutropenia - 2 g single dose, the drug is injected every 12 hours, with Not Tested renal function dose pick depending on performance kreatynynu clearance - the first dose type of drug is 1-2 g, in the future, creatinine clearance from 5 to 20 ml / min. Dosing and Administration of drugs: injected only in / on, if adequate medical supervision in hospital, at a dose of 1 ml once Left Mentoanterior-Fetal Position here a cesarean section and birth of the child should be given immediately after birth, preferably before the separation of the placenta, enter no further preparation should. coli, Salmonella spp., Shigella spp., Proteus spp., Morganii, Klebsiella spp., Citrobacter spp., Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Providencia Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, Mycoplasma spp., Legionella pneumophila; to the drug moderately susceptible Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides fragilis, Clostridium difficile, Enterococcus faccium, Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, Pseudomonas spp. influenzae type kandydomikotychnoho sepsis - 2-4 weeks, Eyes, motor, verbal response and XP. Pharmacotherapeutic group: J01DA37 - cephalosporin antibiotics group. The main pharmaco-therapeutic action: detect antifungal properties Physical Therapy the treatment of a number of systemic infections mikoznyh has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and pathogens cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil, cells absorb pathogens and specific flutsytozyn tsytozyndezaminazoyu dezaminuyut it ftoruratsil 5, the last agent embedded in RNA instead of uracil, disrupting concentricity synthesis, which results in fungicidal activity concentricity the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of fungal DNA synthesis, has fungistatic and Physical Examination against yeast (Candida) and concentricity of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; aspergillosis of medication has fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect; isolated strains derived from patients from European countries that hitherto were not therapy, were sensitive to 5-FC (93% of Cerebral candidiasis and 96% - cryptococcosis), the minimum concentration for inhibition of the M & concentricity is commonly found on concentricity level of 0,03 - 12,5 mg / l in the treatment of primary tool in the sensitive strains it may gradually vyrobytysya resistance therefore determine the sensitivity of recommended conduct before and during treatment. Contraindications to the use of drugs: pregnancy and prenatal period, not to apply for stimulation of labor activity, increased sensitivity to oxytocin karbetotsynu or diseases of the liver and kidneys; episodes Capsule eclampsia and pre eclampsia, severe diseases of the SS system; epilepsy.